Patents Examined by Sabiha N. Qazi
  • Patent number: 11623008
    Abstract: Excipient compositions including a combination of excipients for mucoadhesive pharmaceutical compositions that improve mucoadhesiveness power, as well as release of and adhesion time of suitable active pharmaceutical ingredients (APIs) are disclosed. The excipient compositions include an aqueous solution with a synergistic combination of polymers, such as, for example amylopectin, pullulan, hyaluronic acid, and tamarind xyloglucan, among others. These polymers have been demonstrated to improve the release of as well as the adhesion time of APIs onto mucosa membrane. Mucoadhesive pharmaceutical compositions that include excipient compositions include suitable APIs, such as, for example analgesics, anesthetics, anthelmintics, anti-allergic agents, anti-fungals, antihistamines, anti-inflammatory agents, antimigraine agents, and hormones, among others. Mucoadhesive pharmaceutical compositions including excipient compositions are employed in the treatment of a plurality of mucous membrane diseases.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: April 11, 2023
    Assignee: Professional Compounding Centers of America
    Inventor: Daniel Banov
  • Patent number: 11566000
    Abstract: A cocrystal containing the 1?R-diastereomer and the 1'S-diastereomer of sofpironium bromide at a ratio of 1:3 (Form CO), a crystal mixture (for example, Form B) containing Form CO and a crystalline form of the 1?R-diastereomer (Form MN), and a method for preparing sofpironium bromide, which is suitable for manufacture of the crystal mixture are provided. Form CO and a crystalline form of sofpironium bromide containing Form CO (for example, Form B) have superior stability without hygroscopic property, and accordingly they can be preferably used as a raw material of medicaments.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: January 31, 2023
    Assignee: Botanix SB, Inc.
    Inventors: Kazuyoshi Marubayashi, Masahito Watanabe, Herbert R. Brinkman
  • Patent number: 11529344
    Abstract: This invention relates to combination therapies comprising an EZH2 inhibitor and a chemotherapeutic agent, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: December 20, 2022
    Assignee: Pfizer Inc.
    Inventors: Manfred Kraus, Pei-Pei Kung, Thomas Andrew Paul, Shikhar Sharma, Dominique Verhelle
  • Patent number: 11517555
    Abstract: A solid particulate formulation comprising soluble ferric pyrophosphate and a sachet comprising the solid particulate formulation of soluble ferric pyrophosphate for adding to a dialysis solution are provided. Improved methods of administering soluble ferric pyrophosphate comprising the solid particulate formulations and kits comprising the solid particulate formulation and a dialysis concentrate formulation are also disclosed.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: December 6, 2022
    Assignee: Rockwell Medical, Inc.
    Inventors: Robert Chioini, Ajay Gupta
  • Patent number: 11510896
    Abstract: The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: November 29, 2022
    Inventors: Manuel Rosa-Calatrava, Olivier Terrier, Anaïs Proust, Vincent Moules
  • Patent number: 11464791
    Abstract: The present invention discloses the use of paricalcitol, a synthetic Vitamin D analogue, in the treatment of inflammatory anaemia, preferably in combination with erythropoeisis-stimulating agents. The use of paricalcitol in the treatment of said pathology is associated with a reduced requirement for erythropoeisis-stimulating agents, with optimised iron absorption and with an increase in plasma erythropoietin levels in said patients. The present invention also discloses pharmaceutical compositions that comprise paricalcitol in combination with erythropoeisis-stimulating agents and pharmaceutically acceptable excipients, in addition to the use thereof as drugs in the treatment of inflammatory anaemia.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: October 11, 2022
    Inventor: Miguel Giovanni Uriol Rivera
  • Patent number: 11464788
    Abstract: The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water-soluble oligomer.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: October 11, 2022
    Assignee: Nektar Therapeutics
    Inventors: Wen Zhang, Jennifer Riggs-Sauthier, J. Milton Harris, Michael D. Bentley
  • Patent number: 11458117
    Abstract: Disclosed are the uses of compositions containing not less than 10% w/w of Oroxylin A, not less than 10% w/w of Baicalein and not less than 2% w/w of Chrysin in inhibiting the activity and expression of ? secretase. The invention also discloses the reduction of amyloid content in PS-70 cells using the abovementioned composition. Further, the invention mentions the use of the composition for the therapeutic management of ? secretase mediated disorders.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: October 4, 2022
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
  • Patent number: 11419847
    Abstract: Pharmaceutical micronutrient composition including mixture D in this study helps to mitigate, inhibit, prevent and stop diseases caused by viral infections. The middle east respiratory syndrome-related coronavirus and severe acute respiratory syndrome-related coronavirus as well as their variants and mutants affecting mammals and causing infection are successfully treated using mixture D. Mixture D contains key micronutrients such as an ascorbate, N-acetylcysteine, theaflavins, resveratrol, cruciferous plant extracts, curcumin, quercetin, naringenin, and baicalin and a combination thereof. Additional micronutrients were tested with Mixture D and seemed to have beneficial effects.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: August 23, 2022
    Inventor: Matthias W Rath
  • Patent number: 11384114
    Abstract: Compositions and methods for preparing OXY133 polymorphs Form C to Form I are provided. The methods include subjecting a slurry of OXY133 to conditions sufficient to convert OXY133 to the OXY133 polymorph Form C, polymorph Form D, polymorph Form E, polymorph Form F, polymorph Form G, polymorph Form H, polymorph Form I or a mixture thereof. A polymorph of OXY133 is also provided and that polymorph can be polymorph Form C, polymorph Form D, polymorph Form E, polymorph Form F, polymorph Form G, polymorph Form H, polymorph Form I or a mixture thereof. Pharmaceutical compositions including OXY133 polymorphs are also provided.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: July 12, 2022
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Roger E. Harrington, Jerbrena C. Jacobs
  • Patent number: 11351139
    Abstract: Compositions comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid, an ester derivative, or a pharmaceutically acceptable salt thereof; a triglyceride; and a surfactant, as well as methods for their use. The present disclosure further relates to self-emulsifying drug delivery systems, such as SEDDS, SMEDDS, or SNEDDS comprising 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic acid.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: June 7, 2022
    Assignee: BASF AS
    Inventors: Svein Olaf Hustvedt, Preben Houlberg Olesen, Annette Müllertz
  • Patent number: 11351131
    Abstract: An anti-inflammatory composition is disclosed. The anti-inflammatory composition is useful for a pharmaceutical composition or a cosmetic composition by not only having excellent stability on the skin and therefore being harmless to the human body, but also by controlling the expression of an inflammatory skin disease-related mediating factor and thereby exhibiting an excellent anti-inflammatory effect.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 7, 2022
    Assignee: NEOPHARM CO., LTD.
    Inventors: Ji Yeon Park, Minhee Kim, Bu-Mahn Park, Kyung Sook Yoo, Sung Woo Kim, Hye Seong Shin
  • Patent number: 11267816
    Abstract: The disclosure relates to novel selective Grp94 inhibitors, compositions comprising an effective amount of such compounds, and methods to treat or prevent a condition, such as cancer, comprising administering to an animal in need thereof an effective amount of such compounds.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: March 8, 2022
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Gabriela Chiosis, Pengrong Yan, Pallav Patel, Hardik J. Patel, Tony Taldone, Chenghua Yang, Weilin Sun, Stefan O. Ochiana
  • Patent number: 11260041
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester in combination with G-CSF or in combination with EPO, are provided for the treatment of cytopenia in mammalian subjects. The compositions and methods also reduce the duration of cytopenia such as neutropenia, thrombocytopenia, and/or anemia.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: March 1, 2022
    Assignee: Biosuccess Biotech Co. Ltd.
    Inventor: Zheng Tao Han
  • Patent number: 11191835
    Abstract: The present disclosure relates to novel chlorin-vitamin conjugates and method of making and using the chlorin-vitamin conjugates.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: December 7, 2021
    Assignee: Purdue Research Foundation
    Inventor: Meden Fruel Isaac-Lam
  • Patent number: 11173146
    Abstract: Benzoxazole and indole type KCa3.1 activators as well as the therapeutic uses of such compounds in human or animal subjects and their use in ex vivo preservation of organs or tissues.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: November 16, 2021
    Assignee: The Regents of the University of California
    Inventors: Heike Wulff, Nichole Coleman, Brandon M. Brown, Aida Olivan-Viguera, Ralf Kohler
  • Patent number: 11103514
    Abstract: The present invention resides in the discovery that glucocorticoid receptor antagonists are effective for treating muscular dystrophy including type 1 or type 2 myotonic dystrophy. Treatment methods and kits are provided.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: August 31, 2021
    Assignee: Corcept Therapeutics, Inc.
    Inventor: Joseph Belanoff
  • Patent number: 11098021
    Abstract: Described herein are phenylsulfonamido-benzofuran derivatives, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, methods, uses, and kits involving compounds of Formulae (I), (II), (III), (IV), (V), or (VI) for treating and/or preventing proliferative diseases (e.g. cancers, inflammatory diseases, and autoimmune diseases) in a subject. The compounds and pharmaceutical compositions as described herein inhibit at least one protein of the BCL-2 family in a biological sample or subject to treat and/or prevent a proliferative disease. In certain embodiments, compounds described herein are selective inhibitors of MCL-1, a BCL-2 family member protein.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: August 24, 2021
    Assignees: Memorial Sloan-Kettering Cancer Center, Albert Einstein College of Medicine, Inc.
    Inventors: Emily H. Cheng, Paul Jeng, Ouathek Ouerfelli, James Hsieh, Guangli Yang, Evripidis Gavathiotis
  • Patent number: 11083702
    Abstract: Methods of treating propionic acidemia (PA), methylmalonic acidemia (MMA) and fatty acid oxidation disorders are described. The methods include administering an anaplerotic agent that can directly enter the tricarboxylic acid cycle, such as a succinate derivative or pro-drug, for example trisuccinylglycerol (TSG). Methods of restoring tricarboxylic acid (TCA) cycle function in a cell deficient for propionyl-CoA carboxylase (PCC) or methylmalonyl-CoA mutase (MUT) by contacting the cell with a succinate derivative or pro-drug, such as TSG, are also described.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: August 10, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Gerard Vockley, Al-Walid A. Mohsen
  • Patent number: 11084793
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: August 10, 2021
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal